Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.

Trial Profile

Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms CanaRIa
  • Most Recent Events

    • 07 Nov 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 25 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top